Statement

Data provided by the Ministry of Industry, Department of Chemicals and Petrochemicals

Name & Pack size	Price fixed under DPCO, 79	Price increased	Reduced price after Govt. intervention	% Change
ATS 750 IU 1AMP	2.24	7.26	5.40	—25.6
A TS 750 IU 50 AMP . . .	111.96	341.90	254.54	—25.6
ATS 1500 IU 1AMP . . .	3.54	12.42	9.24	—25.6
ATS 1500 IU 50 AMP . . .	176.92	600.50	452.72	—24.6
ATS 10,000 IU 1 vial . . .	18.62	65.26	48.54	—25.6
ATS 20,000 IU 1 vial . . .	36.27	127.60	94.95	—25.6
ATS 50,000 IU 1 vial . . .	88.30	312.74	232.68	—2556

Purchase of Drugs for T. B. and Leprosy Programmes

1678. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) what was the total value and quantity of each of Rifampimine and Ethambutol formulations purchased by Government for eradication of TB and leprosy programmes during the last three years, year-wise;

(b) the names of the companies from which each medicine was purchased along with quantity and value company-wise;

(c) what was the price at which each medicine was purchased;

(d) what is the procedure of purchase of these medicines;

(e) whether it is a fact that these medicines are being purchased from the same drug companies; and

(f) if so, the reasons therefor?

THE MINISTER OF HEALTH AND FAMILY WELFARE AND THE MINISTER OF CIVIL AVIATION (SHRI MOTI LAL VORA): (a) to (c) The requisite information regarding Rifampicine procured under N.L.E.P. is given in the Annexure. [*See* Appendix CXLVI, Annexure No. 59]

Ethambutol is not purchased under N.L.E.P. The requisite information regarding TB Programme if given in the Annexure. [*See* Appendix CXLVI Annexure No. 60]

(d) to (f) The drugs are purchased from the firms which are on D.G.S. & D. Rate Contract and as per the procedure and rules stipulated by the D.G.S. & D.

Release of Anti-Asthamatic Drugs

1679. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Salbutamol an anti-asthamatic drug has been allowed for marketing under sustained release preparation;

(b) if so, when was such a preparation in this form allowed;